VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24032506 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Bernice Nounamo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Arkansas for Medical Sciences, 4301 W. Markham St., Little Rock, AR 72205, USA. Hauptthemen laut MEDLINE: Proteoglycans, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NCATS NIH HHS, National Institute of Health.
Abstract (Originalsprache)
The anti-CSPG4 monoclonal antibodies (mAbs) have shown anti-tumor activity and therapeutic potential for treating breast cancer. In addition, CSPG4 is a dominant tumor-associated antigen that is also involved in normal-tissue development in humans. Therefore, the potential for off-tumor activity remains a serious concern when targeting CSPG4 therapeutically. Previous work suggested that glycans contribute to the binding of specific anti-CSPG4 antibodies to tumor cells, but the specificity and importance of this contribution are unknown. In this study, the reactivity of anti-CSPG4 mAbs was characterized with a peptide mimetic of carbohydrate antigens expressed in breast cancer. ELISA, flow cytometry, and microarray assays were used to screen mAbs for their ability to bind to carbohydrate-mimicking peptides (CMPs), cancer cells, and glycans. The mAb VT68.2 displayed a distinctly strong binding to a CMP (P10s) and bound to triple-negative breast cancer cells. In addition, VT68.2 showed a higher affinity for N-linked glycans that contain terminal fucose and fucosylated lactosamines. The functional assays demonstrated that VT68.2 inhibited cancer cell migration. These results define the glycoform reactivity of an anti-CSPG4 antibody and may lead to the development of less toxic therapeutic approaches that target tumor-specific glyco-peptides.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Arkansas for Medical Sciences, 4301 W. Markham St., Little Rock, AR 72205, USA.
- Department of Biostatistics, University of Arkansas for Medical Sciences, 4301 W. Markham St., Little Rock, AR 72205, USA.
- Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, 4301 W. Markham St., Little Rock, AR 72205, USA.
- Department of Surgery, Massachusetts General Hospital, Yaw 7, 55 Fruit St, Boston, MA 02114, USA.
ORCID-Profile: Eric Robb Siegel, Steven R Post, Thomas Kelly, Soldano Ferrone
Förderung
- NIGMS NIH HHS
- NCATS NIH HHS
- National Institute of Health
- Arkansas Biosciences Institute
- Center for Microbial Pathogenesis and Host Inflammatory Responses
Zitieren
APA
Nounamo, B., Jousheghany, F., Siegel, E. R., Post, S. R., Kelly, T., Ferrone, S., Kieber-Emmons, T., & Monzavi-Karbassi, B. (2023). VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24032506
Vancouver
Nounamo B, Jousheghany F, Siegel ER, Post SR, Kelly T, Ferrone S, et al. VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24032506
BibTeX
@article{Nounamo2023,
author = {Nounamo, Bernice and Jousheghany, Fariba and Siegel, Eric Robb and Post, Steven R and Kelly, Thomas and Ferrone, Soldano and Kieber-Emmons, Thomas and Monzavi-Karbassi, Behjatolah},
title = {VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24032506}
}
EUVIMED